BioCentury | Jul 18, 2020
Management Tracks

Genzyme vet Modur joins Zikani; plus Scholar Rock, Poseida, Ribon, Kiadis and more

...Cancer company Ribon Therapeutics Inc. named Jodie Morrison as chair. She is CEO of Cadent Therapeutics Inc....
BioCentury | Apr 30, 2020
Finance

April 29 Quick Takes: After ADC approval, Immunomedics raises $420M for rollout; plus Genespire, Vertex, Ocumension and Cadent

...managing director Leon Chen serves as Ocumension’s chairman. Cadent completes $40M series B On Wednesday, Cadent Therapeutics Inc....
...a Phase I schizophrenia trial (see “Neurology Company Cadent Emerges” ). BioCentury Staff HRS7-SN-38, sacituzumab govitecan (IMMU-132) Immunomedics Inc. Cadent Therapeutics Inc. Vertex...
BioCentury | Oct 18, 2019
Company News

Management tracks: Sirtex makes interim CEO permanent; plus Magenta, Pyxis, Stoke, Cadent, StemoniX, Enzyvant, Syapse and Stalicla

...officer. She was SVP, head of legal at Casebia Therapeutics. Movement and cognitive disorders company Cadent Therapeutics Inc....
...which Stalicla is collaborating. Jonathan Block, Associate Editor Enzyvant Sciences GmbH Stoke Therapeutics Inc. Sirtex Medical Ltd. Magenta Therapeutics Inc. Syapse Inc. Cadent Therapeutics Inc. StemoniX...
BioCentury | Aug 21, 2019
Company News

Management tracks: VenatoRx builds out development team; plus Arbutus, Cadent and Arsenal Capital

...NASDAQ:GILD), where he led clinical development for several HIV/AIDS programs. Movement and cognitive disorders company Cadent Therapeutics inc....
...an operating partner. He was most recently a partner at Baird. Jonathan Block, Associate Editor Arbutus Biopharma Corp. Cadent Therapeutics Inc. VenatoRx...
BioCentury | Feb 16, 2019
Company News

Management tracks: Nimbus, Ascentage, Cadent, Skyhawk

...Calif.). The company is developing small molecules for cancer, HBV and age-related diseases. Neurology company Cadent Therapeutics Inc....
BioCentury | Nov 16, 2018
Financial News

Neurology company Cadent emerges with $40M series B

...to treat essential tremor and spinocerebellar ataxia (SCA). Cadent formed via last year's merger between Luc Therapeutics...
...of the tranches. The financing provides runway through the middle of 2020, Curtis said. Through Luc Therapeutics...
...Wotton from Clal Biotechnology and Access Industries joined Cadent's board. Cadent Therapeutics Inc., Cambridge, Mass. Sandi Wong Ataxion Inc. Cadent Therapeutics Luc Therapeutics...
BioCentury | Nov 15, 2018
Financial News

Neurology company Cadent emerges with $40M series B

...to treat essential tremor and spinocerebellar ataxia (SCA). Cadent formed via last year's merger between Luc Therapeutics...
...of the tranches. The financing provides runway through the middle of 2020, Curtis said. Through Luc Therapeutics...
...Qiming and Paul Wotton from Clal Biotechnology and Access Industries joined Cadent's board. Sandi Wong Ataxion Inc. Cadent Therapeutics Luc Therapeutics...
BioCentury | Aug 17, 2017
Finance

Built to purpose

...ongoing Ataxion Inc. Biogen Inc. (NASDAQ:BIIB) Atlas Venture Neurology Single target 2014 2017 Merged with Luc Therapeutics...
BioCentury | Mar 17, 2017
Company News

Ataxion, Luc Therapeutics deal

...for publication. Ataxion Inc. , Cambridge, Mass. Luc Therapeutics Inc. , Cambridge, Mass. Business: Neurology Chris Lieu Ataxion Inc. Luc Therapeutics...
BioCentury | Jun 27, 2016
Emerging Company Profile

Next-gen NMDA

...NMDA receptor modulators for indications that do not currently overlap with Aptinyx's areas of focus. Luc Therapeutics...
...and PTSD. Companies and Institutions Mentioned Allergan plc (NYSE:AGN), Dublin, Ireland Aptinyx Inc., Evanston, Ill. Luc Therapeutics...
Items per page:
1 - 10 of 20
BioCentury | Jul 18, 2020
Management Tracks

Genzyme vet Modur joins Zikani; plus Scholar Rock, Poseida, Ribon, Kiadis and more

...Cancer company Ribon Therapeutics Inc. named Jodie Morrison as chair. She is CEO of Cadent Therapeutics Inc....
BioCentury | Apr 30, 2020
Finance

April 29 Quick Takes: After ADC approval, Immunomedics raises $420M for rollout; plus Genespire, Vertex, Ocumension and Cadent

...managing director Leon Chen serves as Ocumension’s chairman. Cadent completes $40M series B On Wednesday, Cadent Therapeutics Inc....
...a Phase I schizophrenia trial (see “Neurology Company Cadent Emerges” ). BioCentury Staff HRS7-SN-38, sacituzumab govitecan (IMMU-132) Immunomedics Inc. Cadent Therapeutics Inc. Vertex...
BioCentury | Oct 18, 2019
Company News

Management tracks: Sirtex makes interim CEO permanent; plus Magenta, Pyxis, Stoke, Cadent, StemoniX, Enzyvant, Syapse and Stalicla

...officer. She was SVP, head of legal at Casebia Therapeutics. Movement and cognitive disorders company Cadent Therapeutics Inc....
...which Stalicla is collaborating. Jonathan Block, Associate Editor Enzyvant Sciences GmbH Stoke Therapeutics Inc. Sirtex Medical Ltd. Magenta Therapeutics Inc. Syapse Inc. Cadent Therapeutics Inc. StemoniX...
BioCentury | Aug 21, 2019
Company News

Management tracks: VenatoRx builds out development team; plus Arbutus, Cadent and Arsenal Capital

...NASDAQ:GILD), where he led clinical development for several HIV/AIDS programs. Movement and cognitive disorders company Cadent Therapeutics inc....
...an operating partner. He was most recently a partner at Baird. Jonathan Block, Associate Editor Arbutus Biopharma Corp. Cadent Therapeutics Inc. VenatoRx...
BioCentury | Feb 16, 2019
Company News

Management tracks: Nimbus, Ascentage, Cadent, Skyhawk

...Calif.). The company is developing small molecules for cancer, HBV and age-related diseases. Neurology company Cadent Therapeutics Inc....
BioCentury | Nov 16, 2018
Financial News

Neurology company Cadent emerges with $40M series B

...to treat essential tremor and spinocerebellar ataxia (SCA). Cadent formed via last year's merger between Luc Therapeutics...
...of the tranches. The financing provides runway through the middle of 2020, Curtis said. Through Luc Therapeutics...
...Wotton from Clal Biotechnology and Access Industries joined Cadent's board. Cadent Therapeutics Inc., Cambridge, Mass. Sandi Wong Ataxion Inc. Cadent Therapeutics Luc Therapeutics...
BioCentury | Nov 15, 2018
Financial News

Neurology company Cadent emerges with $40M series B

...to treat essential tremor and spinocerebellar ataxia (SCA). Cadent formed via last year's merger between Luc Therapeutics...
...of the tranches. The financing provides runway through the middle of 2020, Curtis said. Through Luc Therapeutics...
...Qiming and Paul Wotton from Clal Biotechnology and Access Industries joined Cadent's board. Sandi Wong Ataxion Inc. Cadent Therapeutics Luc Therapeutics...
BioCentury | Aug 17, 2017
Finance

Built to purpose

...ongoing Ataxion Inc. Biogen Inc. (NASDAQ:BIIB) Atlas Venture Neurology Single target 2014 2017 Merged with Luc Therapeutics...
BioCentury | Mar 17, 2017
Company News

Ataxion, Luc Therapeutics deal

...for publication. Ataxion Inc. , Cambridge, Mass. Luc Therapeutics Inc. , Cambridge, Mass. Business: Neurology Chris Lieu Ataxion Inc. Luc Therapeutics...
BioCentury | Jun 27, 2016
Emerging Company Profile

Next-gen NMDA

...NMDA receptor modulators for indications that do not currently overlap with Aptinyx's areas of focus. Luc Therapeutics...
...and PTSD. Companies and Institutions Mentioned Allergan plc (NYSE:AGN), Dublin, Ireland Aptinyx Inc., Evanston, Ill. Luc Therapeutics...
Items per page:
1 - 10 of 20